Moderna
MRNANASDAQmRNA technology platform enabling rapid development of vaccines and therapeutics across multiple disease areas. Lipid nanoparticle delivery of modified mRNA instructs cells to produce therapeutic proteins.
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-03-26. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-03-26, 236 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
MRNA filings on EDGAR →Cash & investments
$6.91B
at June 30, 2026 (10-Q)
Quarterly operating burn
$578M
average per quarter, Jan–Jun 2026
Cash runway
—
not a runway: funded by operations
Shares outstanding
399.2M
cover page of the latest filing
Read from MRNA's XBRL financial data; latest filing July 31, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
No upcoming catalyst for Moderna has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| mRNA-1283 (next-gen COVID) | COVID-19 (next-generation vaccine) | Phase 3 | Not disclosed | ▼ |
| mRNA-1010 (seasonal flu) | Seasonal influenza | Phase 3 | 2026 | ▼ |
| mRNA-1083 (flu + COVID combo) | Influenza + COVID-19 combination | Phase 3 | 2026 | ▼ |
| mRNA-1345 (RSV) | Respiratory syncytial virus (RSV) in older adults | Approved | Approved May 2024 (mRESVIA) | ▼ |
| mRNA-4157 (V940) + Keytruda | Melanoma (adjuvant, with pembrolizumab) | Phase 3 | 2026-2027 | ▼ |
What does Moderna do?
Moderna is the company that made one of the two big COVID vaccines. That vaccine (Spikevax) made them billions, but as COVID fades from the headlines, investors are asking: what's next? The answer is ambitious. Moderna is using the same mRNA technology — which essentially teaches your cells to make proteins that trigger an immune response — to attack much bigger markets. Their flu vaccine could replace the old-fashioned egg-grown vaccines your doctor gives you every fall. Their combo shot would let you get both your flu and COVID vaccine in a single visit. And their cancer vaccine, developed with Merck, is perhaps the most exciting: it's custom-built for each patient's specific tumor mutations. Here's what makes Moderna interesting for investors right now: the stock is down significantly from its pandemic highs, but the pipeline has never been stronger. They have $9.5 billion in cash, they're already selling an approved RSV vaccine, and they have three potentially massive products in late-stage trials. If even two of these work, the stock has substantial upside from current levels. The risk? All of this is still unproven outside COVID. The flu market is brutally competitive. The cancer vaccine, while promising, is years from peak revenue. And Moderna burns through about $3 billion a year. This is a company with blockbuster potential but real execution risk.
What to watch
Flu vaccine Phase 3 results — this is the make-or-break for near-term revenue diversification. Look for superiority vs. standard flu vaccines, not just non-inferiority
Combo vaccine immune interference data — if combining flu and COVID antigens weakens either response, the product loses its commercial thesis
Q1 2026 earnings call for mRESVIA RSV commercial traction — are doctors prescribing it alongside GSK's Arexvy?
Cash burn trajectory — can Moderna reach cash-flow breakeven from product sales before the $9.5B war chest runs low?
Any updates on the personalized cancer vaccine Phase 3 enrollment pace — slow enrollment would signal commercial scalability concerns
Investment thesis
Moderate RiskBull case
Moderna has the most productive mRNA platform in the world, proven by Spikevax and now mRESVIA. The pipeline is stacked: a flu vaccine that could capture billions in a legacy market, a combo flu+COVID shot that would be first-in-class, and a personalized cancer vaccine that Phase 2 data suggests actually works. With $9.5B in cash and no debt pressure, they can fund all of this internally. If just the combo vaccine and cancer vaccine succeed, Moderna becomes a $100B+ company. The stock has been beaten down from pandemic highs, creating a potential entry point before multiple catalysts hit.
Bear case
Moderna is still overwhelmingly dependent on COVID vaccine revenue, which is declining year over year as pandemic urgency fades. The flu vaccine faces a brutal competitive landscape against cheap, entrenched incumbents — winning market share requires proving not just non-inferiority but meaningful superiority. The cancer vaccine is genuinely exciting but Phase 3 readouts are 12-18 months away and the manufacturing complexity of personalized vaccines could limit commercial scalability. Cash burn is real at ~$3.2B annually, and if the flu and combo trials disappoint, the stock has significant downside from here. The mRNA platform has not yet proven it can succeed outside of pandemic-driven demand.
Risk factors
COVID vaccine revenue decline continues faster than new products can replace it, pressuring cash reserves
Standalone flu vaccine fails to demonstrate superiority over existing vaccines in Phase 3, limiting commercial differentiation
Personalized cancer vaccine manufacturing proves too complex or expensive to scale beyond melanoma
Combination flu+COVID vaccine shows interference between antigens, reducing efficacy of one or both components
mRNA platform safety concerns emerge from long-term post-marketing surveillance, creating regulatory headwinds
Comparable companies
Sponsored
Get premium MRNA analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you